Heron Therapeutics Inc vs International Business Machines Corp — how do they compare? Heron Therapeutics Inc trades at $0.48 (market cap $91.46M), while International Business Machines Corp trades at $211.21 (market cap $200.20B). The key difference: International Business Machines Corp is far larger — about 2188.9× Heron Therapeutics Inc's market cap, and International Business Machines Corp pays a 3.17% dividend while Heron Therapeutics Inc pays none. Which is the better fit depends on your goals.
| HRTX | IBM | |
|---|---|---|
Market Cap | $91.46M | $200.20B |
Sector | Health | Technology |
52-Week High | $1.96 | $329.23 |
52-Week Low | $0.39 | $211.20 |
Enterprise Value | $189.36M | $258.21B |
Volume | — | 4,481,527 |
Dividend Yield | — | 3.17% |
Signals from Pluang's Aura AI — not financial advice
HRTX trades at $0.4804, up 2.06% today, with a bullish technical signal despite mixed earnings. The stock shows a low price-to-sales ratio of 0.51 but negative profitability, with a net income margin of -20.53% in 2026. Recent Q1 2026 earnings missed expectations, though management reaffirmed full-year guidance. Analyst consensus is strongly bullish with 94.7% buy ratings.
Outlook remains speculative given persistent losses and cash burn, but potential upside exists if operational improvements materialize. Key risks include patent litigation outcomes and reliance on revenue growth to achieve profitability. Investors should weigh high analyst optimism against fundamental challenges.
IBM stock trades at $213.81, down 25% following disappointing Q2 2026 preliminary results that missed revenue and EPS estimates. The company maintains strong profitability with 58.4% gross margins and 15.6% net income margin, but faces execution challenges as customers shift spending toward AI infrastructure. Technical indicators show bearish momentum with support at $210 and resistance at $216, while analyst consensus remains positive with a $287.85 price target despite recent downgrades.
IBM's long-term fundamentals remain solid with consistent earnings beats and strong cash flow generation, but near-term headwinds from AI spending shifts create uncertainty. The stock offers value at current levels with attractive valuation multiples, though investors face execution risk and competitive pressure in the evolving AI landscape.
Trailing returns across standard periods
Latest headlines on both assets
Heron Therapeutics is a commercial-stage biotechnology company focused on improving patient care. It develops best-in-class medicines for pain management and cancer care to address unmet medical needs.
Read more on HRTX →International Business Machines Corporation (IBM) provides computer solutions. The Company offers application, technology consulting and support, process design and operations, cloud, digital workplace, and network services, as well as business resiliency, strategy, and design solutions. IBM serves clients worldwide.
Read more on IBM →